Oslo Cancer Cluster recently named three winners in a competition seeking collaborative projects involving immuno-oncology. The three, BerGen Bio, Targovax and Ultimovacs each will receive MNOK 0,4 from Innovation Norway.
BerGenBio will use the award to prove that Axl kinase inhibition may provoke an anti-tumor immune response, working with partners from the University of Bergen, Oslo, University Hospital and the University of Texas.
Targovax plans to work on developing new cancer vaccines, with a focus on the new peptide vaccine TG03 for treatment of RAS mutated malignant melanoma.
Ultimovacs received funding for its project Re-targeting T-cells against cancer – development of T-cell receptors directed against telomerase, with partner Oslo University Hospital. The goal of the project is to develop novel cancer therapies by reprogramming immune cells to target the universal tumor antigen telomerase.
